February 16, 2021 – Aifred Health was named a top 3 finalist in the global IBM Watson XPRIZE dedicated to using AI to solve the world’s grand challenges. Aifred’s AI technology will provide clinicians with decision support to personalize therapeutic choices for depression treatment. Aifred is preparing to launch its regulatory clinical trial in H2 2021 in the United States and Canada. Aifred Health closed a C$4 million seed financing in December 2020.
Contact Information :
Investors & Media: firstname.lastname@example.org
Business Development: email@example.com